Your session is about to expire
← Back to Search
Epcoritamab Combo for Non-Hodgkin's Lymphoma
Study Summary
This trial is assessing the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Approximately 132 adult participants with NHL will be enrolled in 100 sites globally.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition is diagnosed as DLBCL, not otherwise specified.I have been diagnosed with a specific type of lymphoma (DLBCL) that tests positive for CD20.My condition is Grade 3B Follicular Lymphoma.My side effects from previous cancer treatments are mild, except for hair loss.My lymphoma is classified as 'double-hit' or 'triple-hit' according to WHO 2016.My follicular lymphoma is CD20+ Grade 1-3a without turning aggressive.I have a tumor that can be measured on a scan.I can care for myself but may not be able to do heavy physical work.My lymphoma is CD20+ and shows specific genetic features.I have not been treated with epcoritamab or similar drugs.
- Group 1: Arm 3: Dose Expansion
- Group 2: Arm 6: Dose Expansion
- Group 3: Arm 4: Dose Escalation
- Group 4: Arm 5: Dose Expansion
- Group 5: Arm 1: Dose Escalation
- Group 6: Arm 5: Dose Escalation
- Group 7: Arm 6A: Dose Escalation
- Group 8: Arm 6B: Dose Escalation
- Group 9: Arm 7: Dose Escalation
- Group 10: Arm 4: Dose Expansion
- Group 11: Arm 7: Dose Expansion
- Group 12: Arm 2: Dose Escalation
- Group 13: Arm 3: Dose Escalation
- Group 14: Arm 1: Dose Expansion
- Group 15: Arm 2: Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does Epcoritamab have a lot of harmful side effects?
"Because this is a Phase 2 trial, meaning that while there is some safety data, there is no efficacy data, our team at Power has given Epcoritamab a score of 2."
How many locations are conducting this research project?
"Currently, this trial has 29 enrolling patients at locations such as Roswell Park Comprehensive Cancer Center /ID# 242129 in Buffalo, Johns Hopkins University /ID# 242193 in Baltimore, and Memorial Sloan Kettering Cancer Center-Koch Center /ID# 242305 in New york.This question is asking for your opinion:Answer: I believe that the safety of psilocybin should be rated a 3 on Power's scale.Rewritten Answer: In my estimation, the team at Power was right to rate the safety of psilocybin as a 3."
How many people will be included in this experiment at most?
"Indeed, the listing on clinicaltrials.gov verifies that this trial is looking for more patients. The study was first posted on June 14th, 2022 and updated most recently on November 9th, 2022. They are hoping to enroll 132 people total from 29 different sites."
Are there any available slots for participants in this trial?
"Correct. The information available on clinicaltrials.gov affirms that this trial is presently looking for volunteers. This study was originally advertised on 6/14/2022, with the most recent update being 11/9/2022. In total, 132 patients are needed across 29 different sites."
Share this study with friends
Copy Link
Messenger